{"id":"foradil-aerolizer-high-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dysphonia"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Foradil Aerolizer, a high-dose formulation of formoterol, is a long-acting beta2-adrenergic receptor agonist (LABA) used in the maintenance and control of asthma symptoms and to prevent bronchospasm in patients with chronic obstructive pulmonary disease (COPD).","oneSentence":"beta2-adrenergic receptor agonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:35.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT00383721","phase":"PHASE3","title":"Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1196},{"nctId":"NCT00383435","phase":"PHASE3","title":"Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1055},{"nctId":"NCT01641081","phase":"PHASE2","title":"Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Asthma","enrollment":174},{"nctId":"NCT00793624","phase":"PHASE3","title":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":906},{"nctId":"NCT00796653","phase":"PHASE3","title":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":937},{"nctId":"NCT01013753","phase":"PHASE2","title":"A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Asthma","enrollment":198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Formoterol"],"phase":"phase_2","status":"active","brandName":"Foradil Aerolizer, High Dose","genericName":"Foradil Aerolizer, High Dose","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"beta2-adrenergic receptor agonist Used for Asthma, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}